• All
  • Financials
  • Insiders
Webull provides the latest IN8BIO INC (INAB) stock and general news. This information may help you make smarter investment decisions.
About INAB
IN8bio, Inc. is a clinical-stage biotechnology company. The Company is focused on and developing therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The Company's product candidate includes INB-200 and INB-100. INB-200 is genetically modified autologous gamma-delta T cell product candidate that the Company is developing for the treatment of solid tumors. Its indication for INB-200 is glioblastoma (GBM). INB-100 is its allogeneic product candidate that is developed for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation (HSCT). The Company is also developing a portfolio of preclinical programs. INB-400 is its preclinical program focused on developing allogeneic cellular therapies for solid tumor cancers and INB-300 is the preclinical program focused on developing product candidates based on gamma-delta T cells with an added chimeric antigen receptor (CAR).